MP-376

DRUG2 trials

Sponsors

Amgen

Conditions

Chronic Obstructive Pulmonary DiseaseCystic Fibrosis (CF)

Phase 2

Safety, Tolerability and Efficacy of MP-376 Given for 28 Days to Cystic Fibrosis (CF) Patients

CompletedNCT00677365

AmgenCystic Fibrosis (CF)

Start: 2008-06-30End: 2009-06-30Updated: 2024-12-27

A Phase 2 Study of MP-376 to Prevent Acute Exacerbations in Chronic Obstructive Pulmonary Disease (COPD) Patients

CompletedNCT00739648

AmgenChronic Obstructive Pulmonary Disease

Start: 2008-10-31End: 2010-04-30Updated: 2024-12-27

Related Papers

Prevention of exacerbation in patients with moderate-to-very severe COPD with the intent to modulate respiratory microbiome: a pilot prospective, multi-center, randomized controlled trial

Frontiers in Medicine2024-01-054 citations

Measuring respiratory symptoms of COPD: performance of the EXACT- Respiratory Symptoms Tool (E-RS) in three clinical trials.

2014-10-0784 citations

Performance of the EXAcerbations of Chronic Pulmonary Disease Tool Patient-reported Outcome Measure in Three Clinical Trials of Chronic Obstructive Pulmonary Disease

Annals of the American Thoracic Society2014-02-1455 citations

Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa.

2011-02-25101 citations